NCT06574698View on ClinicalTrials.gov

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

RecruitingOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2032

Conditions
NeuroblastomaGD2 Antibody (Naxitamab)
Interventions
DRUG

Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy

Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy

Trial Locations (1)

510000

RECRUITING

Guangzhou Women And Children's Medical Center, Guanzhou

All Listed Sponsors
lead

Guangzhou Women and Children's Medical Center

OTHER